150 related articles for article (PubMed ID: 36986175)
1. Effects of COVID-19 Pandemic on Metabolic Status and Psychological Correlates of a Cohort of Italian NAFLD Outpatients.
Ferri S; Stefanini B; Minguzzi M; Leoni S; Capelli R; Secomandi A; Chen R; Abbati C; Santangeli E; Mattarozzi K; Fabio P
Nutrients; 2023 Mar; 15(6):. PubMed ID: 36986175
[TBL] [Abstract][Full Text] [Related]
2. Impact of Physical Activity Differences Due to COVID-19 Pandemic Lockdown on Non-Alcoholic Fatty Liver Parameters in Adults with Metabolic Syndrome.
Mascaró CM; Bouzas C; Montemayor S; García S; Mateos D; Casares M; Gómez C; Ugarriza L; Borràs PA; Martínez JA; Tur JA
Nutrients; 2022 Jun; 14(12):. PubMed ID: 35745100
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 and non-alcoholic fatty liver disease: Two intersecting pandemics.
Portincasa P; Krawczyk M; Smyk W; Lammert F; Di Ciaula A
Eur J Clin Invest; 2020 Oct; 50(10):e13338. PubMed ID: 32589264
[TBL] [Abstract][Full Text] [Related]
4. Intrahepatic Fat Content and COVID-19 Lockdown in Adults with NAFLD and Metabolic Syndrome.
Montemayor S; Mascaró CM; Ugarriza L; Casares M; Gómez C; Martínez JA; Tur JA; Bouzas C
Nutrients; 2022 Aug; 14(17):. PubMed ID: 36079720
[TBL] [Abstract][Full Text] [Related]
5. Multiplying effects of COVID-19 lockdown on metabolic risk and fatty liver.
Shanmugam H; Di Ciaula A; Di Palo DM; Molina-Molina E; Garruti G; Faienza MF; vanErpecum K; Portincasa P
Eur J Clin Invest; 2021 Jul; 51(7):e13597. PubMed ID: 34032283
[TBL] [Abstract][Full Text] [Related]
6. Impact of COVID-19 Lockdown on Non-Alcoholic Fatty Liver Disease and Insulin Resistance in Adults: A before and after Pandemic Lockdown Longitudinal Study.
López-González ÁA; Altisench Jané B; Masmiquel Comas L; Arroyo Bote S; González San Miguel HM; Ramírez Manent JI
Nutrients; 2022 Jul; 14(14):. PubMed ID: 35889752
[TBL] [Abstract][Full Text] [Related]
7. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population.
Feng RN; Du SS; Wang C; Li YC; Liu LY; Guo FC; Sun CH
World J Gastroenterol; 2014 Dec; 20(47):17932-40. PubMed ID: 25548491
[TBL] [Abstract][Full Text] [Related]
8. MRI-determined liver fat correlates with risk of metabolic syndrome in patients with nonalcoholic fatty liver disease.
Chen J; Duan S; Ma J; Wang R; Chen J; Liu X; Xue L; Xie S; Yao S
Eur J Gastroenterol Hepatol; 2020 Jun; 32(6):754-761. PubMed ID: 32091437
[TBL] [Abstract][Full Text] [Related]
9. Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors.
Barrea L; Muscogiuri G; Modica R; Altieri B; Pugliese G; Minotta R; Faggiano A; Colao A; Savastano S
Front Endocrinol (Lausanne); 2021; 12():649496. PubMed ID: 33815296
[TBL] [Abstract][Full Text] [Related]
10. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
11. The impact of body weight gain on nonalcoholic fatty liver disease and metabolic syndrome during earlier and later adulthood.
Du S; Wang C; Jiang W; Li C; Li Y; Feng R; Sun C
Diabetes Res Clin Pract; 2016 Jun; 116():183-91. PubMed ID: 27321334
[TBL] [Abstract][Full Text] [Related]
12. Non-alcoholic Fatty Liver Disease and COVID-19 Susceptibility and Outcomes: a Korean Nationwide Cohort.
Yoo HW; Jin HY; Yon DK; Effenberger M; Shin YH; Kim SY; Yang JM; Kim MS; Koyanagi A; Jacob L; Smith L; Yoo IK; Shin JI; Lee SW
J Korean Med Sci; 2021 Oct; 36(41):e291. PubMed ID: 34697932
[TBL] [Abstract][Full Text] [Related]
13. Additive effect of non-alcoholic fatty liver disease on the development of diabetes in individuals with metabolic syndrome.
Bae JC; Kim SK; Han JM; Kwon S; Lee DY; Kim J; Park SE; Park CY; Lee WY; Oh KW; Park SW; Rhee EJ
Diabetes Res Clin Pract; 2017 Jul; 129():136-143. PubMed ID: 28527304
[TBL] [Abstract][Full Text] [Related]
14. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome.
Macut D; Tziomalos K; Božić-Antić I; Bjekić-Macut J; Katsikis I; Papadakis E; Andrić Z; Panidis D
Hum Reprod; 2016 Jun; 31(6):1347-53. PubMed ID: 27076501
[TBL] [Abstract][Full Text] [Related]
15. The Influence of Epicardial Fat and Nonalcoholic Fatty Liver Disease on Heart Rate Recovery in Metabolic Syndrome.
Cho KI; Jo EA; Cho SH; Kim BH
Metab Syndr Relat Disord; 2017 Jun; 15(5):226-232. PubMed ID: 28346857
[TBL] [Abstract][Full Text] [Related]
16. [The relationship between non-alcoholic fatty liver disease and metabolic syndrome in patients with latent autoimmune diabetes in adults].
Yu TP; Zhao CC; Chen MY; Lu JX; Li LX; Jia WP
Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(30):2398-2402. PubMed ID: 30138983
[No Abstract] [Full Text] [Related]
17. Gender Differences in the Relationships among Metabolic Syndrome and Various Obesity-Related Indices with Nonalcoholic Fatty Liver Disease in a Taiwanese Population.
Lin IT; Lee MY; Wang CW; Wu DW; Chen SC
Int J Environ Res Public Health; 2021 Jan; 18(3):. PubMed ID: 33498329
[TBL] [Abstract][Full Text] [Related]
18. Interaction between Lifestyle Changes and PNPLA3 Genotype in NAFLD Patients during the COVID-19 Lockdown.
Cinque F; Cespiati A; Lombardi R; Costantino A; Maffi G; Alletto F; Colavolpe L; Francione P; Oberti G; Fatta E; Bertelli C; Sigon G; Dongiovanni P; Vecchi M; Fargion S; Fracanzani AL
Nutrients; 2022 Jan; 14(3):. PubMed ID: 35276911
[TBL] [Abstract][Full Text] [Related]
19. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations.
Milić S; Lulić D; Štimac D
World J Gastroenterol; 2014 Jul; 20(28):9330-7. PubMed ID: 25071327
[TBL] [Abstract][Full Text] [Related]
20. Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome.
Stättermayer AF; Traussnigg S; Aigner E; Kienbacher C; Huber-Schönauer U; Steindl-Munda P; Stadlmayr A; Wrba F; Trauner M; Datz C; Ferenci P
J Trace Elem Med Biol; 2017 Jan; 39():100-107. PubMed ID: 27908400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
